Pulmonary neuroendocrine tumors can present with rare functional syndromes. When acromegaly or hypercalcaemia arises from parathyroid hormone (PTH)-related peptide secretion, a specific treatment approach is indicated beyond standard oncological management.
This protocol applies when a pulmonary neuroendocrine tumor is accompanied by acromegaly or hypercalcaemia related to parathyroid hormone (PTH)-related peptide secretion — a recognised but uncommon functional presentation requiring dedicated clinical attention.
Management of these functional syndromes involves a class of hormonal agents acting on specific receptor targets. The complete protocol — including agent selection, sequencing, and monitoring — is available in full below.
Full regimen details are behind the link below.
DOI: 10.1016/j.annonc.2021.01.003
Other functional syndromes, such as acromegaly or hypercalcaemia, related to parathyroid hormone (PTH)-related peptide secretion, are rare and should be treated with SSAs [V, B].
SSAs are recommended for other functional syndromes such as acromegaly or hypercalcaemia [V, B].
View source ↗